➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Boehringer Ingelheim
McKesson
Express Scripts
Mallinckrodt

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

CLINORIL Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Clinoril patents expire, and when can generic versions of Clinoril launch?

Clinoril is a drug marketed by Merck and is included in one NDA.

The generic ingredient in CLINORIL is sulindac. There are fourteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the sulindac profile page.

US ANDA Litigation and Generic Entry Outlook for Clinoril

A generic version of CLINORIL was approved as sulindac by WATSON LABS on April 3rd, 1990.

  Start Trial

Summary for CLINORIL
Drug patent expirations by year for CLINORIL
Recent Clinical Trials for CLINORIL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Stanley Medical Research InstitutePhase 2
The University of Texas Health Science Center, HoustonPhase 2

See all CLINORIL clinical trials

US Patents and Regulatory Information for CLINORIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck CLINORIL sulindac TABLET;ORAL 017911-001 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial   Start Trial
Merck CLINORIL sulindac TABLET;ORAL 017911-002 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CLINORIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck CLINORIL sulindac TABLET;ORAL 017911-001 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Merck CLINORIL sulindac TABLET;ORAL 017911-002 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Merck CLINORIL sulindac TABLET;ORAL 017911-001 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Merck CLINORIL sulindac TABLET;ORAL 017911-002 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Mallinckrodt
Merck
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.